In mild to moderate AD

Reach for EUCRISA for patients under your care

EUCRISA is the **first and only topical PDE-4 inhibitor** indicated for the topical treatment of mild to moderate AD in patients 2 years of age and older.[1,2*]

AD=atopic dermatitis; PDE-4=phosphodiesterase-4.
* Comparative clinical significance unknown.

eucrisa™
crisaborole ointment 2%

Photographs from the pivotal trials depicting success in ISGA at Day 29[1,3†]



† Actual case. Individual results may vary. May not represent results for all patients.
Adapted from Paller A, et al.

Significantly **more patients** achieved **success in ISGA** at Day 29 vs. vehicle (31.4% vs. 18%; $p \leq 0.001$)‡

Success in ISGA:
defined as score of **CLEAR** (0) or **ALMOST CLEAR** (1) and **≥2-grade improvement from baseline** at Day 29

ISGA=Investigator's Static Global Assessment.
‡ Results from the AD-302 study: a multicentre, double-blind, parallel-group, vehicle-controlled trial of patients aged 2–79 years (mean: 12.6 EUCRISA group; 11.8 vehicle group) with a 5–95% treatable body surface area (baseline mean: 17.9% EUCRISA group; 17.7% vehicle group). Patients were randomized 2:1 to receive EUCRISA (n=513) or vehicle (n=250) applied twice daily for 28 days.

Proven safety and tolerability profile[1]

4-WEEK PIVOTAL TRIALS

Adverse reactions occurring in ≥1% of patients in the 4-week pivotal trials

APPLICATION SITE PAIN[§]

4.45%
(n=45)
EUCRISA (N=1012)

1.20%
(n=6)
Proprietary vehicle ointment (N=499)

48-WEEK, OPEN-LABEL, SINGLE-ARM, LONG-TERM SAFETY STUDY[¶]

Most frequently reported adverse events in patients receiving EUCRISA intermittently (n=517) included:

- Atopic dermatitis
- Application site pain[§]
- Application site infection

Discontinuation rate due to adverse events was 2%.

§ Application site pain refers to skin sensations such as burning or stinging.
¶ 517 patients (including 454 patients aged 2–17 years) who completed the 28-day pivotal trials without safety issues that precluded further treatment were treated with EUCRISA intermittently for up to 48 weeks in 28-day on-treatment or off-treatment cycles.

eucrisa™
crisaborole ointment 2%

OVER **600,000 PATIENTS** TREATED
WITH EUCRISA WORLDWIDE[1‖]

Consider EUCRISA as part of your treatment plan for patients with mild to moderate AD

2x

Apply thin layer topically twice daily

Ages 2 and up

Anywhere on affected skin

Not for ophthalmic, oral, or intravaginal use.

Relevant warnings and precautions

- Hypersensitivity reactions, including contact urticaria
- Use in pregnant and nursing women
- Use in geriatric patients

For more information

Consult the Product Monograph at http://pfizer.ca/pm/en/Eucrisa.pdf for information regarding adverse reactions, drug interactions, and dosing. The Product Monograph is also available by calling 1-800-463-6001.

References: 1. Data on file. Pfizer Canada ULC. **2.** EUCRISA Product Monograph, Pfizer Canada ULC, June 11, 2018. **3.** Paller A, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol* 2016;75(3):494–503.

‖ Clinical significance unknown.

eucrisa™ crisaborole ointment 2%

MEMBER OF INNOVATIVE MEDICINES CANADA

REVIEWED BY PAAB

Pfizer

YOUR PARTNER IN DERMATOLOGY